N. Dhedin and J. Vernant, Allogreffe de cellules souches hématopoïétiques : réalisation et complications. EMC d'hématologie, 2010.

J. Ferrara, J. Levine, P. Reddy, and E. Holler, Graft-versus-host disease. Lancet. 2 mai, pp.1550-61, 2009.

S. Holtan, M. Pasquini, and D. Weisdorf, Acute graft-versus-host disease: a bench-to-bedside update, Blood, vol.124, issue.3, pp.363-73, 2014.
DOI : 10.1182/blood-2014-01-514786

. Agence-de-la-biomédecine, Activité nationale de greffe de CSH, 2012.

E. Copelan, Hematopoietic Stem-Cell Transplantation, New England Journal of Medicine, vol.354, issue.17, pp.1813-1839, 2006.
DOI : 10.1056/NEJMra052638

URL : https://hal.archives-ouvertes.fr/hal-00849640

S. Hymes, A. Alousi, and E. Cowen, Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease, J Am Acad Dermatol. avr, vol.66, issue.4, pp.515-516, 2012.

A. Filipovich, D. Weisdorf, S. Pavletic, G. Socie, J. Wingard et al., National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report, Biology of Blood and Marrow Transplantation, vol.11, issue.12, pp.945-56, 2005.
DOI : 10.1016/j.bbmt.2005.09.004

P. Rowlings, D. Przepiorka, J. Klein, R. Gale, J. Passweg et al., IBMTR Severity INDEX FOR GRADING ACUTE GRAFT-VERSUS-HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE, British Journal of Haematology, vol.97, issue.4, pp.855-64, 1997.
DOI : 10.1046/j.1365-2141.1997.1112925.x

J. Cahn, J. Klein, S. Lee, N. Milpied, D. Blaise et al., Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire, Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 15 août, pp.1495-500, 2005.

D. Jacobsohn and G. Vogelsang, Acute graft versus host disease, Orphanet Journal of Rare Diseases, vol.2, issue.1, p.35, 2007.
DOI : 10.1186/1750-1172-2-35

R. Billingham, The biology of graft-versus-host reactions, Harvey Lect, vol.62, pp.21-78, 19671966.

E. Vargas-díez, J. Fernández-herrera, A. Marin, R. Cámara, and A. García-díez, Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation, British Journal of Dermatology, vol.7, issue.6, pp.1129-1163, 2003.
DOI : 10.1038/sj.bmt.1701334

P. Häusermann, R. Walter, J. Halter, B. Biedermann, A. Tichelli et al., Cutaneous Graft-versus-Host Disease: A Guide for the Dermatologist, Dermatology, vol.216, issue.4, pp.287-304, 2008.
DOI : 10.1159/000113941

P. Martin, G. Schoch, L. Fisher, V. Byers, C. Anasetti et al., A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment, Blood. 15 oct, vol.76, issue.8, pp.1464-72, 1990.

R. Chavan and R. Azhary, Cutaneous graft-versus-host disease: rationales and treatment options, Dermatologic Therapy, vol.10, issue.2, pp.219-247, 2011.
DOI : 10.1111/j.1529-8019.2011.01397.x

K. Lerner, G. Kao, R. Storb, C. Buckner, R. Clift et al., Histopathology of graftvs .-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors, Transplant Proc. déc, vol.6, issue.4, pp.367-71, 1974.

S. Kohler, M. Hendrickson, N. Chao, and B. Smoller, Value of Skin Biopsies in Assessing Prognosis and Progression of Acute Graft-Versus-Host Disease, The American Journal of Surgical Pathology, vol.21, issue.9, pp.988-96, 1997.
DOI : 10.1097/00000478-199709000-00002

M. Tsoi, R. Storb, E. Jones, P. Weiden, H. Shulman et al., Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man, J Immunol Baltim Md, vol.120, issue.5, pp.1485-92, 1950.

G. Girolomoni, C. Pincelli, G. Zambruno, M. Andreani, C. Giardini et al., Immunohistochemistry of Cutaneous Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation, The Journal of Dermatology, vol.60, issue.6, pp.314-337, 1991.
DOI : 10.1111/j.1346-8138.1991.tb03091.x

B. Firoz, S. Lee, P. Nghiem, and A. Qureshi, Role of Skin Biopsy to Confirm Suspected Acute Graft-vs-Host Disease, Archives of Dermatology, vol.142, issue.2, pp.175-82, 2006.
DOI : 10.1001/archderm.142.2.175

Y. Zhou, M. Barnett, and J. Rivers, Clinical Significance of Skin Biopsies in the Diagnosis and Management of Graft-vs-Host Disease in Early Postallogeneic Bone Marrow Transplantation, Archives of Dermatology, vol.136, issue.6, pp.717-738, 2000.
DOI : 10.1001/archderm.136.6.717

R. Storb, H. Deeg, J. Whitehead, F. Appelbaum, P. Beatty et al., Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia, New England Journal of Medicine, vol.314, issue.12, pp.729-764, 1986.
DOI : 10.1056/NEJM198603203141201

V. Ratanatharathorn, R. Nash, D. Przepiorka, S. Devine, J. Klein et al., Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLAidentical sibling bone marrow transplantation, Blood. 1 oct, vol.92, issue.7, pp.2303-2317, 1998.

T. Ruutu, A. Gratwohl, T. De-witte, B. Afanasyev, J. Apperley et al., Prophylaxis and treatment of GVHD: EBMT???ELN working group recommendations for a standardized practice, Bone Marrow Transplantation, vol.92, issue.2, pp.168-73, 2014.
DOI : 10.1016/j.bbmt.2010.05.011

C. Brunstein, J. Barker, D. Weisdorf, T. Defor, J. Miller et al., Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease, Blood, vol.110, issue.8, pp.3064-70, 2007.
DOI : 10.1182/blood-2007-04-067215

S. Choi and P. Reddy, Current and emerging strategies for the prevention of graft-versus-host disease, Nature Reviews Clinical Oncology, vol.118, issue.9, pp.536-583, 2014.
DOI : 10.1002/cncr.24198

R. Nash, J. Antin, C. Karanes, J. Fay, B. Avalos et al., Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors, Blood. 15 sept, vol.96, issue.6, pp.2062-2070, 2000.

B. Bolwell, R. Sobecks, B. Pohlman, S. Andresen, L. Rybicki et al., A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation, Bone Marrow Transplantation, vol.34, issue.7, pp.621-626, 2004.
DOI : 10.1038/sj.bmt.1704647

J. Finke, C. Schmoor, H. Lang, K. Potthoff, and H. Bertz, Matched and Mismatched Allogeneic Stem-Cell Transplantation From Unrelated Donors Using Combined Graft-Versus-Host Disease Prophylaxis Including Rabbit Anti???T Lymphocyte Globulin, Journal of Clinical Oncology, vol.21, issue.3, pp.506-519, 2003.
DOI : 10.1200/JCO.2003.03.129

A. Bacigalupo, T. Lamparelli, P. Bruzzi, S. Guidi, P. Alessandrino et al., Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO), Blood, vol.98, issue.10, pp.2942-2949, 2001.
DOI : 10.1182/blood.V98.10.2942

F. Dignan, A. Clark, P. Amrolia, J. Cornish, G. Jackson et al., Diagnosis and management of acute graft-versus-host disease, British Journal of Haematology, vol.50, issue.1, pp.30-45, 2012.
DOI : 10.1111/j.1365-2141.2012.09129.x

T. Furlong, R. Storb, C. Anasetti, F. Appelbaum, H. Deeg et al., Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities, Bone Marrow Transplantation, vol.26, issue.9, pp.985-91, 2000.
DOI : 10.1038/sj.bmt.1702639

D. Weisdorf, R. Haake, B. Blazar, W. Miller, P. Mcglave et al., Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome, Blood. 15 févr, vol.75, issue.4, pp.1024-1054, 1990.

M. Van-lint, G. Milone, S. Leotta, C. Uderzo, R. Scimè et al., Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin, Blood, vol.107, issue.10, pp.4177-81, 2006.
DOI : 10.1182/blood-2005-12-4851

M. Mielcarek, B. Storer, M. Boeckh, P. Carpenter, G. Mcdonald et al., Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes, Blood, vol.113, issue.13, pp.2888-94, 2009.
DOI : 10.1182/blood-2008-07-168401

M. Van-lint, C. Uderzo, A. Locasciulli, I. Majolino, R. Scimé et al., Early treatment of acute graft-versus-host disease with high-or low-dose 6- methylprednisolone: a multicenter randomized trial from the Italian Group for, Bone Marrow Transplantation. Blood. 1 oct, vol.92, issue.7, pp.2288-93, 1998.

H. Greinix, R. Knobler, N. Worel, B. Schneider, A. Schneeberger et al., The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease, Haematologica. mars, vol.91, issue.3, pp.405-413, 2006.

F. Patriarca, A. Sperotto, D. Damiani, G. Morreale, F. Bonifazi et al., Infliximab treatment for steroid-refractory acute graft-versus-host disease, Haematologica. nov, vol.89, issue.11, pp.1352-1361, 2004.

D. Couriel, R. Saliba, M. De-lima, S. Giralt, B. Andersson et al., A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation, vol.15, issue.12, pp.1555-62, 2009.
DOI : 10.1016/j.bbmt.2009.08.003

A. Benito, T. Furlong, P. Martin, C. Anasetti, F. Appelbaum et al., Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease, Transplantation. 27 déc, vol.72, issue.12, 2001.

C. Onishi, K. Ohashi, T. Sawada, M. Nakano, T. Kobayashi et al., A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease, International Journal of Hematology, vol.30, issue.Suppl 2, pp.464-70, 2010.
DOI : 10.1007/s12185-010-0516-x

J. Bay, N. Dhédin, M. Goerner, J. Vannier, A. Marie-cardine et al., Inolimomab in Steroid-Refractory Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis and Comparison with Other Interleukin-2 Receptor Antibodies, Transplantation, vol.80, issue.6, pp.782-790, 2005.
DOI : 10.1097/01.TP.0000173995.18826.DE

J. Piñana, D. Valcárcel, R. Martino, M. Moreno, A. Sureda et al., Encouraging Results with Inolimomab (Anti-IL-2 Receptor) as Treatment for Refractory Acute Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation, vol.12, issue.11, pp.1135-1176, 2006.
DOI : 10.1016/j.bbmt.2006.06.010

M. Schmidt-hieber, T. Fietz, W. Knauf, L. Uharek, W. Hopfenmüller et al., Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease, British Journal of Haematology, vol.75, issue.4, pp.568-74, 2005.
DOI : 10.1046/j.1365-2141.2001.02582.x

L. Tong and S. Worswick, Viral infections in acute graft-versus-host disease: A review of diagnostic and therapeutic approaches, Journal of the American Academy of Dermatology, vol.72, issue.4, pp.696-702, 2015.
DOI : 10.1016/j.jaad.2014.12.002

H. Byun, J. Yang, B. Kim, and K. Cho, Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions, Journal of the American Academy of Dermatology, vol.65, issue.4, pp.726-758, 2011.
DOI : 10.1016/j.jaad.2010.07.042

N. Mittmann, S. Knowles, M. Koo, N. Shear, A. Rachlis et al., Incidence of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in an HIV Cohort, American Journal of Clinical Dermatology, vol.115, issue.9102, pp.49-54, 2012.
DOI : 10.2165/11593240-000000000-00000

R. Schwartz, P. Mcdonough, and B. Lee, Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis, J Am Acad Dermatol. août, vol.69, issue.2, pp.173-174, 2013.

F. Pereira, A. Mudgil, and D. Rosmarin, Toxic epidermal necrolysis, Journal of the American Academy of Dermatology, vol.56, issue.2, pp.181-200, 2007.
DOI : 10.1016/j.jaad.2006.04.048

J. Roujeau, Drug-induced toxic epidermal necrolysis. II. Current aspects, Clinics in Dermatology, vol.11, issue.4, pp.493-500, 1993.
DOI : 10.1016/0738-081X(93)90156-7

J. Saurat, J. Lachapelle, D. Lipsker, and L. Thomas, Nécrolyse épidermique toxique (syndrome de Lyell) Dermatologie et infections sexuellement transmissibles. 5ème édition, Masson

L. Blum, O. Chosidow, G. Rostoker, C. Philippon, J. Revuz et al., Renal involvement in toxic epidermal necrolysis, Journal of the American Academy of Dermatology, vol.34, issue.6, pp.1088-90, 1996.
DOI : 10.1016/S0190-9622(96)90297-2

F. Lebargy, P. Wolkenstein, M. Gisselbrecht, F. Lange, J. Fleury-feith et al., Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study, Intensive Care Medicine, vol.123, issue.12, pp.1237-1281, 1997.
DOI : 10.1007/s001340050492

H. Autorité and D. Santé, Nécrolyse épidermique toxique (syndromes de Stevens- Johnson et de Lyell) : protocole national de diagnostic et de soin, 2010.

M. Mockenhaupt, C. Viboud, A. Dunant, L. Naldi, S. Halevy et al., Stevens???Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study, Journal of Investigative Dermatology, vol.128, issue.1, pp.35-44, 2008.
DOI : 10.1038/sj.jid.5701033

J. Roujeau, J. Guillaume, J. Fabre, D. Penso, M. Fléchet et al., Toxic Epidermal Necrolysis (Lyell Syndrome), Archives of Dermatology, vol.126, issue.1, pp.37-42, 1981.
DOI : 10.1001/archderm.1990.01670250043005

B. Sassolas, C. Haddad, M. Mockenhaupt, A. Dunant, Y. Liss et al., ALDEN, an Algorithm for Assessment of Drug Causality in Stevens???Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case???Control Analysis, Clinical Pharmacology & Therapeutics, vol.40, issue.1, pp.60-68, 2010.
DOI : 10.1016/0895-4356(96)00035-2

D. Dobrosavljevic, M. Milinkovic, and M. Nikolic, Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination, Journal of the European Academy of Dermatology and Venereology, vol.12, issue.1, pp.59-61, 1999.
DOI : 10.1001/archderm.131.6.669

G. Grieb, M. Alazemi, R. Das, S. Dunda, P. Fuchs et al., A Rare Case of Toxic Epidermal Necrolysis with Unexpected Fever Resulting from Dengue Virus, Case Reports in Dermatology, vol.2, issue.3, pp.189-94, 2010.
DOI : 10.1159/000322963

D. Khalaf, B. Toema, N. Dabbour, and F. Jehani, Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis., Mediterranean Journal of Hematology and Infectious Diseases, vol.3, issue.1, p.2011004, 2011.
DOI : 10.4084/mjhid.2011.004

A. Garza, A. Waldman, and J. Mamel, A case of toxic epidermal necrolysis with involvement of the GI tract after systemic contrast agent application at cardiac catheterization, Gastrointestinal Endoscopy, vol.62, issue.4, pp.638-680, 2005.
DOI : 10.1016/j.gie.2005.06.034

L. Valeyrie-allanore, S. Bastuji-garin, S. Guégan, N. Ortonne, M. Bagot et al., Prognostic value of histologic features of toxic epidermal necrolysis, Journal of the American Academy of Dermatology, vol.68, issue.2, pp.29-35, 2013.
DOI : 10.1016/j.jaad.2011.10.007

P. Friedmann, I. Strickland, M. Pirmohamed, and B. Park, Investigation of Mechanisms in Toxic Epidermal Necrolysis Induced by Carbamazepine, Archives of Dermatology, vol.130, issue.5, pp.598-604, 1994.
DOI : 10.1001/archderm.1994.01690050066011

A. Quinn, K. Brown, B. Bonish, J. Curry, K. Gordon et al., Uncovering Histologic Criteria With Prognostic Significance in Toxic Epidermal Necrolysis, Archives of Dermatology, vol.141, issue.6, pp.683-690, 2005.
DOI : 10.1001/archderm.141.6.683

A. Nassif, A. Bensussan, L. Boumsell, A. Deniaud, H. Moslehi et al., Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells, Journal of Allergy and Clinical Immunology, vol.114, issue.5, pp.1209-1224, 2004.
DOI : 10.1016/j.jaci.2004.07.047

M. Caproni, D. Torchia, E. Schincaglia, W. Volpi, A. Frezzolini et al., The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum, British Journal of Dermatology, vol.6, issue.2, pp.319-343, 2006.
DOI : 10.1046/j.1523-1747.2000.00816.x

O. Correia, L. Delgado, J. Ramos, C. Resende, and J. Torrinha, Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement, Archives of Dermatology, vol.129, issue.4, pp.466-474, 1993.
DOI : 10.1001/archderm.129.4.466

M. Tohyama, H. Watanabe, S. Murakami, Y. Shirakata, K. Sayama et al., Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis, British Journal of Dermatology, vol.86, issue.2, pp.322-352, 2012.
DOI : 10.1111/j.1365-2133.2011.10649.x

W. Pichler, D. Naisbitt, and B. Park, Immune pathomechanism of drug hypersensitivity reactions, Journal of Allergy and Clinical Immunology, vol.127, issue.3, pp.74-81, 2011.
DOI : 10.1016/j.jaci.2010.11.048

J. Castrejon, N. Berry, S. El-ghaiesh, B. Gerber, W. Pichler et al., Stimulation of human T cells with sulfonamides and sulfonamide metabolites, Journal of Allergy and Clinical Immunology, vol.125, issue.2, pp.411-419, 2010.
DOI : 10.1016/j.jaci.2009.10.031

W. Chung, S. Hung, J. Yang, S. Su, S. Huang et al., Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis, Nature Medicine, vol.203, issue.12, pp.1343-50, 2008.
DOI : 10.1038/nm.1884

R. Abe, N. Yoshioka, J. Murata, Y. Fujita, and H. Shimizu, Granulysin as a Marker for Early Diagnosis of the Stevens???Johnson Syndrome, Annals of Internal Medicine, vol.151, issue.7, pp.514-519, 2009.
DOI : 10.7326/0003-4819-151-7-200910060-00016

J. Murata, R. Abe, and H. Shimizu, Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment, Journal of Allergy and Clinical Immunology, vol.122, issue.5, pp.992-1000, 2008.
DOI : 10.1016/j.jaci.2008.06.013

I. Viard, P. Wehrli, R. Bullani, P. Schneider, N. Holler et al., Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin, Science, vol.282, issue.5388, pp.490-493, 1998.
DOI : 10.1126/science.282.5388.490

P. Ghislain and J. Roujeau, Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome, Dermatol Online J. juin, vol.8, issue.1, p.5, 2002.

S. Bastuji-garin, N. Fouchard, M. Bertocchi, J. Roujeau, J. Revuz et al., SCORTEN: a severity-of-illness score for toxic epidermal necrolysis, J Invest Dermatol. août, vol.115, issue.2, pp.149-53, 2000.

I. Garcia-doval, L. Lecleach, H. Bocquet, X. Otero, and J. Roujeau, Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome, Archives of Dermatology, vol.136, issue.3, pp.323-330, 2000.
DOI : 10.1001/archderm.136.3.323

L. Valeyrie-allanore, S. Ingen-housz-oro, C. A. Thuillot, D. Sigal, M. Binhas et al., Prise en charge de la douleur dans le syndrome de Stevens-Johnson/Lyell et les autres dermatoses bulleuses ??tendues, Annales de Dermatologie et de V??n??r??ologie, vol.138, issue.10, pp.694-701, 2011.
DOI : 10.1016/j.annder.2011.05.029

A. Furubacke, G. Berlin, C. Anderson, and F. Sjöberg, Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?, Intensive Care Medicine, vol.25, issue.11, pp.1307-1317, 1999.
DOI : 10.1007/s001340051063

S. Engelhardt, M. Schurr, and R. Helgerson, Toxic Epidermal Necrolysis, Journal of Burn Care & Rehabilitation, vol.18, issue.6, pp.520-524, 1997.
DOI : 10.1097/00004630-199711000-00009

J. Van-der-meer, M. Schuttelaar, G. Toth, S. Kardaun, G. Beerthuizen et al., Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam, Clinical and Experimental Dermatology, vol.140, issue.8, pp.654-660, 2001.
DOI : 10.1001/archderm.131.6.669

P. Wolkenstein, J. Latarjet, J. Roujeau, C. Duguet, S. Boudeau et al., Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis, The Lancet, vol.352, issue.9140, pp.1586-1595, 1998.
DOI : 10.1016/S0140-6736(98)02197-7

K. Brown, G. Silver, M. Halerz, P. Walaszek, A. Sandroni et al., Toxic Epidermal Necrolysis: Does Immunoglobulin Make a Difference?, Journal of Burn Care & Rehabilitation, vol.25, issue.1, pp.81-89, 2004.
DOI : 10.1097/01.BCR.0000105096.93526.27

L. Valeyrie-allanore, S. Katsahyan, D. Tu-anh, D. Prost, N. Sbidian et al., Communication orale 90: Mortalité du SJS-NET et impact de la ciclosporine: étude rétrospective de 130 patients, Journées Dermatologiques de Paris, 2014.

R. Schwartz, P. Mcdonough, and B. Lee, Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment, J Am Acad Dermatol. août, vol.69, issue.2, pp.187-188, 2013.

B. Mcdonald, J. Singer, and J. Bianco, Toxic Epidermal Necrolysis Possibly Linked to Aztreonam in Bone Marrow Transplant Patients, Annals of Pharmacotherapy, vol.101, issue.1, pp.34-39, 1992.
DOI : 10.1177/106002809202600109

J. Zakrzewski, G. Lentini, U. Such, A. Duerr, V. Tran et al., Toxic epidermal necrolysis: differential diagnosis of an epidermolytic dermopathy in a hematopoietic stem cell transplant recipient, Bone Marrow Transplantation, vol.30, issue.5, pp.331-334, 2002.
DOI : 10.1038/sj.bmt.1703624

M. Schaich, K. Schäkel, T. Illmer, G. Ehninger, and M. Bornhäuser, Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation, Ann Hematol. mai, vol.82, issue.5, pp.303-307, 2003.

I. Hilgendorf, J. Casper, L. Sviland, F. Prall, C. Junghanss et al., Toxic epidermal necrolysis after allogeneic haematopoietic stem cell transplantation, Bone Marrow Transplantation, vol.23, issue.4, pp.245-251, 2007.
DOI : 10.1038/sj.bmt.1705572

R. Goiriz, P. Peñas, S. Pérez-gala, Y. Delgado-jiménez, M. Aragüés et al., Stage IV cutaneous acute graft-versus-host disease. Clinical and histological study of 15 cases, Journal of the European Academy of Dermatology and Venereology, vol.157, issue.12, pp.1398-404, 2009.
DOI : 10.1111/j.1468-3083.2009.03326.x

G. Villada, J. Roujeau, C. Cordonnier, M. Bagot, M. Kuentz et al., Toxic epidermal necrolysis after bone marrow transplantation: Study of nine cases, Journal of the American Academy of Dermatology, vol.23, issue.5, pp.870-875, 1990.
DOI : 10.1016/0190-9622(90)70307-4

F. Macedo, J. Faris, L. Lum, A. Gabali, J. Uberti et al., Extensive Toxic Epidermal Necrolysis Versus Acute Graft Versus Host Disease After Allogenic Hematopoietic Stem-Cell Transplantation, Journal of Burn Care & Research, vol.35, issue.6, pp.431-436, 2014.
DOI : 10.1097/BCR.0000000000000040

M. Campos, C. Campos, F. Aarestrup, and B. Aarestrup, Oral mucositis in cancer treatment: Natural history, prevention and treatment, Mol Clin Oncol. mai, vol.2, issue.3, pp.337-377, 2014.

S. Paczesny, T. Braun, J. Levine, J. Hogan, J. Crawford et al., Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin, Science Translational Medicine, vol.2, issue.13, pp.13-15, 2010.
DOI : 10.1126/scitranslmed.3000406

Y. Chen and C. Cutler, Biomarkers for acute GVHD: can we predict the unpredictable?, Bone Marrow Transplantation, vol.11, issue.6, pp.755-60, 2013.
DOI : 10.1016/j.exphem.2006.02.013

S. Paczesny, O. Krijanovski, T. Braun, S. Choi, S. Clouthier et al., A biomarker panel for acute graft-versus-host disease, Blood, vol.113, issue.2, pp.273-281, 2009.
DOI : 10.1182/blood-2008-07-167098